← Evidence map

TrialOncotarget2017

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Guénaëlle Levallet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

10 papers cite it

2017

2018

2019

2020

2021

2022

this papercites it

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. | OpenQuestion